Advertisement
Canada markets open in 6 hours 17 minutes
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7308
    -0.0013 (-0.18%)
     
  • CRUDE OIL

    78.48
    0.00 (0.00%)
     
  • Bitcoin CAD

    87,095.50
    -830.05 (-0.94%)
     
  • CMC Crypto 200

    1,367.43
    +2.31 (+0.17%)
     
  • GOLD FUTURES

    2,328.40
    -2.80 (-0.12%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • NASDAQ futures

    18,186.50
    -9.00 (-0.05%)
     
  • VOLATILITY

    13.49
    0.00 (0.00%)
     
  • FTSE

    8,213.49
    0.00 (0.00%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6787
    -0.0005 (-0.07%)
     

Stocks in play: Zenith Epigenetics Ltd.

Has entered into an agreement with Astellas Pharma Inc. to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC). Zenith Epigenetics Ltd. shares T.RVX are trading up $0.02 at $0.93.

Read: Sky-High Demand for Drone Technology Driving Massive Growth